DRI HEALTHCARE TRUST (DHT-UN.CA) Stock Price, Forecast & Analysis
Canada - TSX:DHT-UN - CA23344H1091
15.33 CAD
+0.08 (+0.52%)
We assign a fundamental rating of 5 out of 10 to DHT-UN. DHT-UN was compared to 31 industry peers in the Pharmaceuticals industry. DHT-UN has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on DHT-UN.
1. Profitability
1.1 Basic Checks
In the past year DHT-UN was profitable.
DHT-UN had a positive operating cash flow in the past year.
1.2 Ratios
DHT-UN has a Return On Assets of 0.41%. This is in the better half of the industry: DHT-UN outperforms 70.97% of its industry peers.
DHT-UN has a Return On Equity of 0.78%. This is in the better half of the industry: DHT-UN outperforms 70.97% of its industry peers.
DHT-UN has a Return On Invested Capital of 3.82%. This is in the better half of the industry: DHT-UN outperforms 70.97% of its industry peers.
The Average Return On Invested Capital over the past 3 years for DHT-UN is significantly below the industry average of 7.77%.
The last Return On Invested Capital (3.82%) for DHT-UN is above the 3 year average (1.94%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.41% | ||
| ROE | 0.78% | ||
| ROIC | 3.82% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
1.3 Margins
DHT-UN has a Profit Margin of 2.11%. This is in the better half of the industry: DHT-UN outperforms 74.19% of its industry peers.
The Operating Margin of DHT-UN (25.45%) is better than 93.55% of its industry peers.
DHT-UN's Operating Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.45% | ||
| PM (TTM) | 2.11% | ||
| GM | N/A |
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
DHT-UN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for DHT-UN remains at a similar level compared to 1 year ago.
DHT-UN has a worse debt/assets ratio than last year.
2.2 Solvency
DHT-UN has an Altman-Z score of 1.47. This is a bad value and indicates that DHT-UN is not financially healthy and even has some risk of bankruptcy.
DHT-UN has a Altman-Z score of 1.47. This is amongst the best in the industry. DHT-UN outperforms 80.65% of its industry peers.
The Debt to FCF ratio of DHT-UN is 3.05, which is a good value as it means it would take DHT-UN, 3.05 years of fcf income to pay off all of its debts.
DHT-UN's Debt to FCF ratio of 3.05 is amongst the best of the industry. DHT-UN outperforms 90.32% of its industry peers.
A Debt/Equity ratio of 0.77 indicates that DHT-UN is somewhat dependend on debt financing.
DHT-UN's Debt to Equity ratio of 0.77 is on the low side compared to the rest of the industry. DHT-UN is outperformed by 74.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 3.05 | ||
| Altman-Z | 1.47 |
ROIC/WACC0.5
WACC7.7%
2.3 Liquidity
A Current Ratio of 1.83 indicates that DHT-UN should not have too much problems paying its short term obligations.
With a Current ratio value of 1.83, DHT-UN perfoms like the industry average, outperforming 51.61% of the companies in the same industry.
A Quick Ratio of 1.83 indicates that DHT-UN should not have too much problems paying its short term obligations.
DHT-UN has a better Quick ratio (1.83) than 77.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
DHT-UN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.89%.
The Earnings Per Share has been growing slightly by 5.09% on average over the past years.
Looking at the last year, DHT-UN shows a quite strong growth in Revenue. The Revenue has grown by 16.24% in the last year.
DHT-UN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.25% yearly.
EPS 1Y (TTM)-11.89%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%4.08%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%6.07%
3.2 Future
DHT-UN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.70% yearly.
DHT-UN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.44% yearly.
EPS Next Y-3.93%
EPS Next 2Y3.69%
EPS Next 3Y9.29%
EPS Next 5Y17.7%
Revenue Next Year10.7%
Revenue Next 2Y6.25%
Revenue Next 3Y6.95%
Revenue Next 5Y14.44%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
DHT-UN is valuated cheaply with a Price/Earnings ratio of 7.13.
DHT-UN's Price/Earnings ratio is rather cheap when compared to the industry. DHT-UN is cheaper than 90.32% of the companies in the same industry.
When comparing the Price/Earnings ratio of DHT-UN to the average of the S&P500 Index (26.06), we can say DHT-UN is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 6.57, the valuation of DHT-UN can be described as very cheap.
87.10% of the companies in the same industry are more expensive than DHT-UN, based on the Price/Forward Earnings ratio.
DHT-UN is valuated cheaply when we compare the Price/Forward Earnings ratio to 32.73, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.13 | ||
| Fwd PE | 6.57 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, DHT-UN is valued cheaper than 87.10% of the companies in the same industry.
83.87% of the companies in the same industry are more expensive than DHT-UN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.79 | ||
| EV/EBITDA | 8.11 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.69%
EPS Next 3Y9.29%
5. Dividend
5.1 Amount
DHT-UN has a Yearly Dividend Yield of 4.57%, which is a nice return.
DHT-UN's Dividend Yield is rather good when compared to the industry average which is at 3.19. DHT-UN pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.36, DHT-UN pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
5.2 History
DHT-UN has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y3.69%
EPS Next 3Y9.29%
TSX:DHT-UN (11/7/2025, 7:00:00 PM)
15.33
+0.08 (+0.52%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners56.4%
Inst Owner ChangeN/A
Ins Owners0.89%
Ins Owner ChangeN/A
Market Cap846.06M
Revenue(TTM)186.77M
Net Income(TTM)3.93M
Analysts80
Price Target20.34 (32.68%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.57% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.27%
Min EPS beat(2)-21.52%
Max EPS beat(2)0.99%
EPS beat(4)3
Avg EPS beat(4)5.31%
Min EPS beat(4)-21.52%
Max EPS beat(4)39.35%
EPS beat(8)5
Avg EPS beat(8)18.26%
EPS beat(12)7
Avg EPS beat(12)90.58%
EPS beat(16)8
Avg EPS beat(16)66.21%
Revenue beat(2)0
Avg Revenue beat(2)-0.5%
Min Revenue beat(2)-0.64%
Max Revenue beat(2)-0.37%
Revenue beat(4)2
Avg Revenue beat(4)14.3%
Min Revenue beat(4)-0.64%
Max Revenue beat(4)46.19%
Revenue beat(8)5
Avg Revenue beat(8)27.34%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)6.34%
PT rev (3m)-2.9%
EPS NQ rev (1m)2.7%
EPS NQ rev (3m)20%
EPS NY rev (1m)0.68%
EPS NY rev (3m)-0.85%
Revenue NQ rev (1m)0.86%
Revenue NQ rev (3m)3.9%
Revenue NY rev (1m)0.12%
Revenue NY rev (3m)1.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.13 | ||
| Fwd PE | 6.57 | ||
| P/S | 4.53 | ||
| P/FCF | 5.79 | ||
| P/OCF | 5.79 | ||
| P/B | 1.68 | ||
| P/tB | N/A | ||
| EV/EBITDA | 8.11 |
EPS(TTM)2.15
EY14.02%
EPS(NY)2.33
Fwd EY15.22%
FCF(TTM)2.65
FCFY17.28%
OCF(TTM)2.65
OCFY17.28%
SpS3.38
BVpS9.12
TBVpS-4.91
PEG (NY)N/A
PEG (5Y)N/A
Graham Number21.01
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.41% | ||
| ROE | 0.78% | ||
| ROCE | 5.31% | ||
| ROIC | 3.82% | ||
| ROICexc | 4.21% | ||
| ROICexgc | 90.74% | ||
| OM | 25.45% | ||
| PM (TTM) | 2.11% | ||
| GM | N/A | ||
| FCFM | 78.26% |
ROA(3y)4.16%
ROA(5y)N/A
ROE(3y)6.27%
ROE(5y)N/A
ROIC(3y)1.94%
ROIC(5y)N/A
ROICexc(3y)2.05%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.74%
ROCE(5y)N/A
ROICexgc growth 3Y44.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.25%
ROICexc growth 5YN/A
OM growth 3Y-6.12%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.19
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.77 | ||
| Debt/FCF | 3.05 | ||
| Debt/EBITDA | 2.61 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 97.99% | ||
| Profit Quality | 3716.37% | ||
| Current Ratio | 1.83 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 1.47 |
F-Score6
WACC7.7%
ROIC/WACC0.5
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.89%
EPS 3Y5.09%
EPS 5YN/A
EPS Q2Q%4.08%
EPS Next Y-3.93%
EPS Next 2Y3.69%
EPS Next 3Y9.29%
EPS Next 5Y17.7%
Revenue 1Y (TTM)16.24%
Revenue growth 3Y32.25%
Revenue growth 5YN/A
Sales Q2Q%6.07%
Revenue Next Year10.7%
Revenue Next 2Y6.25%
Revenue Next 3Y6.95%
Revenue Next 5Y14.44%
EBIT growth 1Y343.32%
EBIT growth 3Y24.15%
EBIT growth 5YN/A
EBIT Next Year104.78%
EBIT Next 3Y26.53%
EBIT Next 5Y29.34%
FCF growth 1Y103.46%
FCF growth 3Y19.16%
FCF growth 5YN/A
OCF growth 1Y103.46%
OCF growth 3Y19.16%
OCF growth 5YN/A
DRI HEALTHCARE TRUST / DHT-UN.CA FAQ
What does DRI HEALTHCARE TRUST do?
DRI Healthcare Trust is an unincorporated open-ended company. The company is headquartered in Toronto, Ontario and currently employs 36 full-time employees. The company went IPO on 2021-02-11. The firm provides capital to universities and research institutions, academic institutions, biotechnology companies and pharmaceutical companies. The company acquires more than 75 royalties on 45-plus drugs, including Ekterly, Eylea, Keytruda, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. Its portfolio includes Empaveli/Syfovre, Eylea I, Eylea II, Natpara, Omidria, Oracea, Orserdu I, Orserdu II, Rydapt, Spinraza, Stelara, Vonjo I, Vonjo II, Xenpozyme, Xolair, Zejula, Zytiga, and other products. Its therapeutic areas include oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, lysosomal storage disorders (LSD) and immunology. The firm is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Galderma, and others.
Can you provide the latest stock price for DRI HEALTHCARE TRUST?
The current stock price of DHT-UN.CA is 15.33 CAD. The price increased by 0.52% in the last trading session.
How is the ChartMill rating for DRI HEALTHCARE TRUST?
DHT-UN.CA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.